Postgraduate research

DT3-001 Developing a new online intervention to target transdiagnostic processes in anxiety and depression

• 3 years
• King's College London
• Dementias and Neurodegeneration

DT3-002 Developing a digital intervention to support food-related quality of life and disordered eating in people living with inflammatory bowel disease

• 3 years
• EMBL-EBI
• Genomics and Rare Diseases

DT3-003 Inclusive human-centred design of novel therapeutic targets in a digitally supported therapy for psychosis

• 3 years
• Lund University
• Dementias and Neurodegeneration

DT3-004 Improving access to an evidence-based digital therapeutic for treating depression and anxiety in long-term conditions (COMPASS) for Black Asian and Minority Ethnic (BAME) groups

• 3 years
• Lund University
• Genomics and Rare Diseases

IN3-001 Evaluating the impact of medication side effects and increasing their recognition in clinical practice

• 3 years
• Geisinger
• Genomics and Rare Diseases

IN3-002 Multimodal machine learning in electronic health records for prognosis and diagnosis of rare neurological disorders

• 3 years
• University of Oxford
• Dementias and Neurodegeneration

PA3-001 Using ecological momentary assessment to innovate the biopsychosocial assessment and treatment of pain in people with Parkinson’s

• 3 years
• University of Cambridge
• Metabolic and Endocrine Disorders

PA3-002 Understanding Pain Mechanisms of Central Sensitization in Humans Using functional MRI, Psychometric and Psychophysical Assessment

• 3 years
• University of Cambridge
• Public Health and Prevention

TG3-001 Polygenic stratification of mental disorders to explore differential environmental exposures, clinical profiles, and treatment response

• 3 years
• Washington University
• Public Health and Prevention

PP3-001 atient and carer involvement in personalization and measuring treatment efficacy

• 3 years
• Generative AI Laboratory
• Metabolic and Endocrine Disorders

CO4-001 sing real-world evidence to emulate the cost-effectiveness of different treatment sequences of antipsychotic medication

• 4 years
• University of Edinburgh
• Genomics and Rare Diseases

CO4-002 ncovering GABAergic mechanisms in people at clinical high-risk for psychosis through pharmacological MRI

• 4 years
• Queen Mary University of London
• Public Health and Prevention

CO4-003 Neural Markers of Prospective Negative Thought in Anxiety, A Computational and Pharmaco-Physiological Analysis

• 4 years
• Milner Therapeutics Institute
• Dementias and Neurodegeneration

CO4-004 Identification of modifiable risk factors for increased health care use in people with dementia and developing opportunities for intervention

• 4 years
• University of Manchester
• Genomics and Rare Diseases

CO4-005 An experimental medicine study of cannabidiol (CBD) and dronabinol as treatments for cannabis use disorder in teenagers who regularly use cannabis

• 4 years
• AstraZeneca
• Public Health and Prevention

CO4-006 What works in supporting people with mental health problems into work: a data linkage study

• 4 years
• University of Oxford
• Genomics and Rare Diseases

CO4-007 A multi-centre, double-blind, parallel-group, randomized controlled study to compare the efficacy of real versus sham external Trigeminal Nerve Stimulation (eTNS) on symptoms in youth with Attention Deficit/Hyperactivity Disorder (ADHD) (ATTENS)

• 4 years
• Queen Mary University of London
• Public Health and Prevention

CO4-008 Assessing a novel oculomotor biomarker of Attention Deficit/Hyperactivity Disorder (ADHD) and examining the efficacy of anti-saccade eye movement training as a novel intervention.

• 4 years
• Wellcome Sanger Institute
• Public Health and Prevention

CO4-009 Towards tailored treatment: Predicting real-world outcomes to first-line augmentation interventions for treatment-resistant depression

• 4 years
• Lund University
• Dementias and Neurodegeneration

CO4-010 Feasibility and acceptability of speech and mood data collection in daily life after traumatic brain injury (TBI) using digital technology

• 4 years
• University of Edinburgh
• Genomics and Rare Diseases

CO4-011 Enhancing psychosis prevention through dynamic refinement of a clinical prediction model using machine learning

• 4 years
• AstraZeneca
• Genomics and Rare Diseases

CO4-012 The iADJUST study: Examining the trajectories of depressive and anxiety symptoms among incident dialysis patients and testing the feasibility of a tailored psychological intervention to improve mental health outcomes

• 4 years
• Generative AI Laboratory
• Genomics and Rare Diseases

CO4-013 Suicidal behaviour: An investigation of online temporal trends and electronic health records

• 4 years
• Baillie Gifford Pandemic Science Hub
• Genomics and Rare Diseases

CO4-014 Social media, mental health and self-harm behaviour in young people

• 4 years
• Washington University
• Genomics and Rare Diseases

CO4-015 Biomarkers for Autism and ADHD using EEG Data with Regularized Multivariate Statistical Methods.

• 4 years
• Imperial
• Dementias and Neurodegeneration

CO4-016 Understanding how anti-inflammatories help people with depression

• 4 years
• Milner Therapeutics Institute
• Dementias and Neurodegeneration

CO4-017 Shifting dynamic functional brain dynamics using pharmacological challenges in adults with and without autism spectrum disorder

• 4 years
• Precision Life
• Public Health and Prevention

CO4-018 Cannabidiol for psychosis in Parkinson’s disease psychosis

• 4 years
• Wellcome Sanger Institute
• Public Health and Prevention

CO4-019 Experimental TESTing on Heroin and opioid OverDose: Environmental, Respiratory and Pharmacological Mechanisms (OD-TEST).

• 4 years
• Queen Mary University of London
• Dementias and Neurodegeneration

CO4-020 Exploring the neurochemical and cognitive mechanisms underlying a novel EEG biomarker for autism.

• 4 years
• University of Edinburgh
• Public Health and Prevention

CO4-021 Biopsychosocial mechanisms underpinning the association between a singing intervention for mothers with postnatal depression and improvements in the mother-infant relationship

• 4 years
• University of Oxford
• Dementias and Neurodegeneration

CO4-022 Biomarker discovery using pharmaceutical challenge: shiftability studies to probe neural underpinnings.

• 4 years
• AstraZeneca
• Genomics and Rare Diseases

CO4-023 Infant Predictors of Behavioural and Developmental Outcomes in Early-Onset Epilepsy: Integrating Neurocognition and Electronic Health Records

• 4 years
• EMBL-EBI
• Genomics and Rare Diseases

CO4-024 Ketamine and reward: understanding the effects on function and physiology in responders and non-responders

• 4 years
• Baillie Gifford Pandemic Science Hub
• Dementias and Neurodegeneration

CO4-025 Neuroimaging signatures of the antidepressant response to ketamine

• 4 years
• University of Cambridge
• Dementias and Neurodegeneration

CO4-026 Dissecting the Epigenetic Basis of Eating Disorders in EDGI and Nanopore DNA Methylation Sequencing Data

• 4 years
• Imperial
• Genomics and Rare Diseases

CO4-027 Identifying Drug Repositioning Opportunities Through Leveraging the Core Neurogenetics of Major Depressive Disorder

• 4 years
• University of Oxford
• Genomics and Rare Diseases

CO4-028 Identifying social and behavioural intervention targets to reduce the impact of cardiovascular disease on mental health

• 4 years
• University of Exeter
• Genomics and Rare Diseases

CO4-029 Making life with psychosis easier: evaluation of a portable, capillary sampling device to reduce the burden of routine monitoring of full blood count in people taking clozapine.

• 4 years
• Precision Life
• Genomics and Rare Diseases

CO4-030 Synaptic connectivity in Schizophrenia

• 4 years
• King's College London
• Dementias and Neurodegeneration

CO4-031 Identifying trajectories of psychiatric risk and resilience during development (THRIVE)

• 4 years
• Washington University
• Dementias and Neurodegeneration

CO4-032 The role of glutamatergic function in the neurobiology of treatment-resistant schizophrenia

• 4 years
• University of Exeter
• Dementias and Neurodegeneration

CO4-033 Using deep phenotyping informatics to map the prevalence, process and outcomes of people with neuropsychiatric disorders

• 4 years
• Generative AI Laboratory
• Dementias and Neurodegeneration

CO4-034 Developing novel diagnostic biomarkers for Functional Neurological Disorder

• 4 years
• EMBL-EBI
• Genomics and Rare Diseases

CO4-035 Machine learning approaches to high-dimensional mediation: explaining outcomes following psychological therapy for anxiety or depressive disorders

• 4 years
• Precision Life
• Dementias and Neurodegeneration

CO4-036 Flexible machine learning models to capture the dynamics of patient outcomes at scale: learning from routinely- and remotely-collected health data

• 4 years
• Geisinger
• Genomics and Rare Diseases

CO4-037 Cohort identification for mental health clinical trials: a knowledge graph approach

• 4 years
• University of Manchester
• Genomics and Rare Diseases

CO4-038 Developing an open-source speech analysis toolkit for clinical applications

• 4 years
• BioFair
• Genomics and Rare Diseases

CO4-039 How does trauma-focused psychological therapy for dual diagnosis psychosis and Post-Traumatic Stress Disorder patients affect the mind and brain?

• 4 years
• Baillie Gifford Pandemic Science Hub
• Public Health and Prevention

CO4-040 Virtual Reality Boosted Cognitive Remediation for People with Psychosis to Improve Recovery Outcomes

• 4 years
• Imperial
• Dementias and Neurodegeneration

CO4-041 Targeting Cognitive Inflexibility to Augment Anxiety Treatments for Autistic Youth: A precision psychiatry approach

• 4 years
• Wellcome Sanger Institute
• Genomics and Rare Diseases

CO4-042 Identifying a transdiagnostic biomarker of dissociative states in health and disease

• 4 years
• BioFair
• Dementias and Neurodegeneration

CO4-043 Developing neurophysiological and cognitive biomarkers for antipsychotic response in First Episode of Psychosis

• 4 years
• Geisinger
• Dementias and Neurodegeneration

CO4-044 Using virtual reality to investigate sense of body ownership and agency in patients with functional neurological disorder and patients with schizophrenia.

• 4 years
• Milner Therapeutics Institute
• Public Health and Prevention

CO4-045 Exploring Multi-omics based Machine Learning approaches for the prediction of disease progression and patient stratification in clinical trials of neuropsychiatric disorders

• 4 years
• King's College London
• Public Health and Prevention

CO4-046 Selectively shifting the GABA system in autism; a promising target for interventions?

• 4 years
• University of Exeter
• Public Health and Prevention

CO4-047 Novel digital tools and therapies to improve the mental health of autistic people.

• 4 years
• University of Manchester
• Genomics and Rare Diseases

CO4-048 Transcranial Direct Current Stimulation and Virtual Reality Exposure Therapy for Anorexia Nervosa

• 4 years
• BioFair
• Public Health and Prevention